Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Approximately 50%-95% of prostate cancer patients undergoing radiation therapy (RT) develop
symptomatic urinary problems .These symptoms can significantly diminish a patient's quality
of life during and shortly after therapy. Alpha1-blockers, such as Rapaflo, act to decrease
resistance to urinary flow.
This multi-institutional phase III trial is designed to compare standard of care versus
preventive treatment with Rapaflo for prostate cancer patients, regardless of risk group,
whose treatment consists of radical radiation therapy. We plan to recruit 188 patients across
Quebec who will be randomized into two arms: rapaflo prescribed at start of radiation therapy
or if/when symptoms appear.